Drugs / DKN-01

Trials 14 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT02375880 Jun 2015 → Jul 2018 cholangiocarcinoma, gallbladder carcinoma Leap Therapeutics, Inc. Completed No outcome recorded
Phase 1 NCT02013154 May 2014 → Jul 2019 gastric adenocarcinoma, gastroesophageal cancer, gastroesophageal junction adenocarcinoma, neoplasm of esophagus +1 Leap Therapeutics, Inc. Completed No outcome recorded
Phase 1 NCT01711671 May 2013 → Jul 2015 plasma cell myeloma Leap Therapeutics, Inc. Completed No outcome recorded
Phase 1 NCT01457417 Jan 2012 → Dec 2013 non-small cell lung carcinoma, plasma cell myeloma Leap Therapeutics, Inc. Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT04166721 Feb 2020 → Mar 2025 overdue esophageal cancer, gastric cancer Royal Marsden NHS Foundation Trust Active not recruiting No outcome recorded
Phase 1/2 NCT03837353 Apr 2019 → Jul 2022 prostate cancer NYU Langone Health Terminated No outcome recorded
Phase 1/2 NCT03645980 Oct 2018 → Aug 2021 hepatocellular carcinoma Johannes Gutenberg University Mainz Unknown No outcome recorded
Phase 26 trials
Phase 2 NCT05761951 Aug 2023 → Jan 2027 expected endometrial cancer M.D. Anderson Cancer Center Active not recruiting No outcome recorded
Phase 2 NCT05480306 Aug 2022 → Jul 2025 colorectal adenocarcinoma Leap Therapeutics, Inc. Completed No outcome recorded
Phase 2 NCT04363801 Jul 2020 → Mar 2025 gastric adenocarcinoma, gastroesophageal cancer Leap Therapeutics, Inc. Terminated No outcome recorded
Phase 2 NCT03818997 Dec 2019 → Apr 2021 biliary tract cancer, esophageal cancer, gastroesophageal cancer European Organisation for Research and Treatment of Cancer - EORTC Withdrawn No outcome recorded
Phase 2 NCT04057365 Oct 2019 → Sep 2022 biliary tract cancer Massachusetts General Hospital Terminated No outcome recorded
Phase 2 NCT03395080 Mar 2018 → Sep 2020 carcinosarcoma, endometrial cancer, ovarian cancer Leap Therapeutics, Inc. Completed No outcome recorded
Phase not stated1 trial
NCT04681248 carcinosarcoma, endometrial cancer, gastric adenocarcinoma, gastroesophageal cancer +4 Leap Therapeutics, Inc. No longer available No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 16 sources stand behind the page.

FieldValueCited text
Known as DKN-01 “This trial is designed to evaluate the safety and efficacy of administering DKN-01, a DKK1 inhibitor plus atezolizumab, an anti-PD-L1 monoclonal antibody in this patient cohort.” NCT04166721
13

NCT01711671

NCT02375880

NCT03395080

NCT04681248

NCT05480306

NCT03645980

NCT02013154

NCT04057365

NCT04363801

NCT03837353

NCT01457417

NCT03818997

NCT05761951

Known as Formerly LY2812176 Formerly LY2812176NCT01457417
Known as LY-2812176 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297562
Known as Sirexatamab ChEMBL registry synonym — accepted as the source's own label CHEMBL4297562
Action Inhibit “neutralizing activity against Dkk-1” NCT02375880
Modality Monoclonal antibody “humanized monoclonal antibodyNCT02375880
Route Intravenous “DKN-01 will be administered intravenously (IV) once a week” NCT01457417
Target DKK1 “DKN-01-a humanized mAb targeting DKK1-was evaluated” PMID 32878766 Sep 2020